Condition
Dosimetry
Total Trials
4
Recruiting
0
Active
0
Completed
3
Success Rate
75.0%-12% vs avg
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 87/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
75.0%
-11.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed with results
Key Signals
75% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (2)
P 1 (2)
Trial Status
Completed3
Terminated1
Trial Success Rate
75.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT06398392Not ApplicableCompletedPrimary
Radiation Dosimetry of the 18 kDa Translocator Protein Ligand [18F]PBR111 in Humans
NCT04467567Not ApplicableCompletedPrimary
Dosimetry Using a CZT-camera Following LUTATHERA® Therapy
NCT00250172Phase 1CompletedPrimary
PET Whole Body Biodistribution and Test Retest Bain Imaging Studies Using a Phosphodiesterase 4 Inhibitor (R)-[11C]Rolipram
NCT01420952Phase 1TerminatedPrimary
Imaging of Brain Receptors Using (11C)mGlu1
Showing all 4 trials